Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

Lara C. Pullen, PhD  |  Issue: March 2019  |  March 19, 2019

Healthcare providers prescribe many different drugs to treat osteoporosis, including bisphosphonates.

Kidney Disease & Fracture Risk

Susan Ott, MD, professor of medicine and metabolism at the University of Wisconsin School of Medicine in Madison, discussed bone health in patients with chronic kidney disease (CKD) who have high fracture risk that presents throughout all stages of disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

These patients have increased bone turnover due to multiple factors associated with CKD, Dr. Ott explained. Patients with renal failure have difficulty excreting phosphate, a situation that affects bone metabolism because calcium and phosphate are in a complex feedback loop with parathyroid hormone (PTH) and vitamin D.

Patients with CKD also have low levels of bone morphogenic protein 7 (BMP-7), which is necessary for differentiation of pre-osteoblasts to mature osteoblasts. This loss of BMP-7 causes the histologic finding known as fibrosis. In addition, patients may be malnourished, which can contribute to decreased bone formation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with CKD may also experience the accumulation of iron, aluminum and strontium in the bone, which can contribute to osteomalacia and oxalate in the bone, which can cause crystal deposition. Moreover, dialysis does not clear beta-2 microglobulin, so patients on long-term dialysis can form amyloid that can subsequently create cysts and cause carpal tunnel syndrome. The cysts frequently form at the end of a long bone, and, when the diagnosis is missed by a nephrologist, the patient is frequently referred to a rheumatologist.

Dr. Ott explained that for patients with slightly low PTH, the best option may be treatment with raloxifene or possibly anti-sclerostin, when available. She also noted that most nephrologists treat patients with mild to moderate kidney disease with denosumab. Unfortunately, the safety of bisphosphonates in patients with decreased kidney function is unknown, and the effectiveness of teriperatide in patients with high PTH due to kidney disease is unknown.

“We have a really complex set of symptoms,” Dr. Ott concluded. “It will be hard to find treatments when there are so many things going wrong. You just take them one at a time, and do what you can.”


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)bisphosphonateschronic kidney diseaseOsteoporosis

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences